TIDMIXI
RNS Number : 3606D
IXICO plc
19 February 2020
19 February 2020
IXICO plc
("IXICO" or the "Company")
IXICO to Present AI Segmentation Research at Huntington's
Disease Therapeutics Conference
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience , today announces that it is scheduled to
present a scientific poster on enhancing imaging analysis accuracy
for Huntington's Disease (HD) by comparing two types of Artificial
Intelligence (AI) techniques at the CHDI Foundation 15 (th) Annual
2020 Huntington's Disease Therapeutics Conference held from 24 - 27
February, 2020 in Palm Springs, California, USA.
Further details of the presentation are as follows:
Title: Fully automatic AI segmentation of subcortical regions:
comparison of ATLAS and deep-learning based approaches
Wednesday, 26th February, Group B: Human Studies at 2.30 - 4pm,
Poster number 101
Authors: Kirsi M Kinnunen (1*,) Jack Weatheritt (1) , Richard
Joules (1) , Robin Wolz (1,2)
Changes in the volume of the caudate and putamen regions are
used as biomarkers to track the development of Huntington's disease
and monitor the potential effect of interventional treatments.
Accurate volume calculations, obtained via segmentations, are
therefore of utmost clinical importance. This poster compares and
contrasts two AI approaches for anatomical segmentation - the first
is an established atlas-based manifold learning technique, IXICO's
proprietary LEAP technology; the second is a deep-learning model
based on a 3D convolutional neural network (CNN).
Dr Robin Wolz, Senior Vice President, Science & Innovation
at IXICO commented: "Huntington's Disease continues to be a focus
for IXICO in its efforts to provide pioneering technologies to
support the advancement of effective treatments for rare
neurological diseases. Our research in imaging analytics will
provide an insight into the best methods for monitoring both the
progression of the disease as well as the potential effect of
interventional treatments."
1) IXICO plc, London, UK 2) Imperial College London, London, UK.
*Presenting author.
IXICO will be attending /presenting at upcoming conferences:
Neurodegenerative Drug Development Summit : 25-27 February 2020,
Hyatt Regency Boston, Boston, USA
ARCA Global Conference : 2-3 March 2020, Sheraton Denver
Downtown, Denver, USA
IXICO will be presenting at the conference.
The Wearable Technology Show : 10-11 March 2020, The Business
Design Centre, London, UK
ADPD Focus Meeting : 2-5 April 2020, Austria Center, Vienna,
Austria
SCA Global Conference : 6-7 April 2020: German Center for
Neurodegenerative Diseases, Bonn, Germany
IXICO will be presenting and co-sponsoring the event.
BioTrinity 2020 : 28-29 April 2020, etc.venues, 155 Bishopsgate
, London, UK
17 (th) Annual Anglonordic Life Science Conference: 23-24 June 2020, County Hall, London, UK
For further information please contact:
IXICO plc +44 (0) 20 3763 7498
Alison Howie, Chief Product Officer
Optimum Strategic Communications +44 (0) 203 950 9144
Mary Clark / Supriya Mathur / Manel Mateus
IXICO@optimumcomms.com
About IXICO
IXICO's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience.
Our goal is to be a leading proponent in the use of Artificial
Intelligence (AI) in clinical development, to improve biopharma
R&D productivity through the adoption of breakthrough data
analytics in precision healthcare. Through the deployment of novel
AI algorithms, we analyse and interpret brain scans and digital
biosensor data to enable better trial design, patient selection and
ultimately clinical outcomes across all phases of clinical
evaluation. Our data analytics services are deployed on some of the
most important clinical trials in neuroscience, providing valuable
insights to disease progression and patient safety, enabling our
clients to make better informed decisions earlier in the clinical
development pathway.
More information is available on www.IXICO.com
About CHDI Foundation
CHDI Foundation is a privately-funded, not-for-profit biomedical
research organization devoted to a single disease - Huntington's
disease (HD). The foundation's mission is to develop drugs that
will slow the progression of Huntington's disease and provide
meaningful clinical benefit to patients as quickly as possible. To
achieve this CHDI manages a diverse portfolio of research projects
through a novel virtual model that encourages scientific
collaboration to more directly connect academic research, drug
discovery and clinical development. This helps bridge the
translational gap that often exists between academic and industrial
research pursuits, and which adds costly delays to therapeutic
development. The foundation's activities extend from exploratory
biology to the identification and validation of therapeutic
targets, and from drug discovery and development to clinical
studies and trials.
This year, CHDI Foundation is organising its 15(th) annual
Huntington's Disease Therapeutics Conference. A forum for drug
discovery and development, the conference brings together
colleagues in the field to share ideas and make connections in the
pursuit of therapeutics for Huntington's disease.
For more information, please visit
https://chdifoundation.org/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUWVARRRUUAAR
(END) Dow Jones Newswires
February 19, 2020 04:00 ET (09:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From May 2024 to Jun 2024
Ixico (LSE:IXI)
Historical Stock Chart
From Jun 2023 to Jun 2024